FDA blasts Alkermes for underselling the risks of Vivitrol Lowers tolerance, raises profits – DECEMBER 11, 2019 - “Vivitrol is being promoted in a way that does not adequately present important risk information in a truthful and non-misleading manner,” Thomas Abrams, directo... Read More...Dec 17 2019